Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 179

Diffuse Intrinsic Pontine Glioma.

In tumors like DIPG, the diagnosis itself spells a death sentence for the child affected. For several decades, none of the altered fractionation radiotherapy or additional chemotherapy or targeted agents have shown a significant benefit over conventional radiotherapy. We propose amalgamation of several known and tested hypothesis in DIPG ...

Multi-modal Epigenetic Pt(IV) Prodrugs for Paediatric High Grade Gliomas

Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive cancers - DIPG has a survival rate of 1% at 5 years. Platinum(II) anti-cancer drugs (e.g. carboplatin) are used in combination with sodium valproate to treat DIPG clinically, with the intact blood brain barrier being effectively bypassed by convection enhanced delivery. We ...

Targeting Group 4 medulloblastoma via Musashi1-cell cycle inhibition

Despite recent progress in medulloblastoma treatment, two main problems remain. High risk groups 3 and 4 medulloblastoma patients still show a high rate of mortality. Even in the case of success, patients are frequently left with devastating neurocognitive and other sequelae. Therefore, more effective and less aggressive therapies are still in demand. ...

Investigating the use of Copper chelation therapy in DIPG: a ...

The development of genomics has led to a comprehensive delineation of Diffuse Intrinsic Pontine Glioma (DIPG) heterogenous mutational landscape. This includes several interconnected cellular processes that can be pursued by drugs targeting cellular copper called chelating agents. These drugs bind copper and prevent its use in the cell. Copper ...

Harnessing brain resident immune cells to attack high risk medulloblastoma ...

ABSTRACT We focus on family desires to find therapies that improve cure rates, whilst minimizing long-term side effects for deadly brain cancers. Given radiotherapy (RT) is a common brain cancer treatment, our collaborative team focusses on drugs that enhance RT for high-risk medulloblastoma patients. A major caveat in past childhood ...